share_log

Bellerophon Therapeutics Shares Are Trading Higher After the FDA Accepted the Company's Proposal to Reduce the Study Size for Its Ongoing Registrational REBUILD Phase 3 Trial of INOpulse for the Treatment of Fibrotic Interstitial Lung Disease.

Benzinga ·  Sep 27, 2022 15:31
Bellerophon Therapeutics shares are trading higher after the FDA accepted the company's proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment